Seaport Therapeutics, Inc. — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Seaport Therapeutics filed its Q2 2026 10-Q on August 3, 2026, for the period ending June 30, 2026. The filing document index shows standard quarterly disclosures (financial statements, officer certifications, XBRL data) with 79 supporting documents. No specific financial metrics, deal announcements, guidance changes, leadership changes, or material events are detailed in the available filing header or metadata provided.
Why this rating
Routine quarterly SEC filing with no disclosed material events; standard administrative disclosure for a $227.7M-asset biotech firm.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.